newsFDA grants Orphan Drug Designation to DYN101 treatment12 August 2019 | By Victoria Rees (European Pharmaceutical Review)A treatment for Centronuclear Myopathies has received Orphan Drug Designation from the FDA and will begin Phase I/II trials.